来自ergot真菌的尼克尔戈林在阻断人类5-HT3A受体中的分子机制
Minsu Pyeon1, Myungmi Moon1, Jeongyeon Yun1
1Department of Biotechnology and Department of Integrative Food, Bioscience and Biotechnology (BK21 FOUR), Chonnam National University, Gwangju 61186, Republic of Korea.
Journal of microbiology and biotechnology
|January 24, 2025
概括
尼克尔戈林通过阻断其开放通道来抑制5-基三胺3A (5-HT3A) 受体. 这种作用表明对认知功能和焦虑有潜在的益处,为神经退行性疾病提供治疗可能性.
科学领域:
- 神经药理学神经药理学
- 分子生物学分子生物学
背景情况:
- 5西胺3A (5-HT3A) 受体与神经传递,认知功能和吐有关.
- 过度激活5-HT3A受体会导致焦虑,记忆障碍,恶心和吐.
研究的目的:
- 研究尼塞戈林对5-HT3A受体的调节作用.
- 确定尼塞戈林与5-HT3A受体相互作用的机制.
主要方法:
- 两电极电压电生理学测量5-HT诱导电流.
- 分子对接研究,以预测结合相互作用.
主要成果:
- 尼克戈林证明了可逆,度依赖,电压依赖和使用依赖的5-HT3A受体活性抑制.
- 尼克尔戈林作为一种开放通道阻断剂.
- 分子对接表明与结合残留物L260和V264.4的相互作用.
结论:
- 尼克尔戈林抑制了5-HT3A受体的活动,这表明了潜在的治疗应用.
- 抑制可以改善认知功能和减少焦虑,有利于痴呆症和其他疾病患者.
- 尼克戈林作为5-HT3A抗剂的作用需要对神经退行性疾病进行进一步的研究.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
930
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
930
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
204
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
204
Drugs Acting on Autonomic Ganglia: Blockers
952
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
952
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.1K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.1K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
852
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
852


